Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers in genitourinary neoplasia.

M J Droller

    Cancer
    |August 1, 1987
    PubMed
    Summary

    Biologic response modifiers show promise for genitourinary cancers, with bacillus Calmette-Guerin (BCG) effective for bladder cancer. Interferon and interleukin-2 offer limited success for renal cell carcinoma, highlighting the need for further research.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors.

    Urologic oncology·2011
    Same author

    Standardization in pathologic assessment of transitional cell cancer of the bladder.

    Urologic oncology·2011
    Same author

    Translational research in urology: From the laboratory to the clinic.

    Urologic oncology·2011
    Same author

    Risk factors in clonal development from superficial to invasive bladder cancer.

    Cancer surveys·2004
    Same author

    Putative protein markers in the sera of men with prostatic neoplasms.

    BJU international·2003
    Same author

    Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer.

    Prostate cancer and prostatic diseases·2002

    Area of Science:

    • Uro-oncology
    • Immunotherapy
    • Biologic Response Modifiers

    Background:

    • Genitourinary cancers, excluding testis cancer, exhibit limited responsiveness to conventional chemotherapy.
    • Biologic response modifiers (BRMs) are being investigated for their potential to prevent tumor progression via direct action or immune system modulation.
    • Key BRMs include interferon, recombinant gamma interferon, bacillus Calmette-Guerin (BCG), tumor necrosis factor, prostaglandin synthetase inhibitors, and interleukin-2.

    Purpose of the Study:

    • To review the efficacy and mechanisms of various biologic response modifiers in treating genitourinary cancers.
    • To assess the current status and future potential of BRMs in uro-oncology.

    Main Methods:

    • Review of existing literature on the use of BRMs in genitourinary cancers.
    • Analysis of reported treatment outcomes and suggested mechanisms of action for agents like interferon, BCG, and interleukin-2.

    Main Results:

    • Topical BCG demonstrates significant success (70% rate) in treating superficial transitional cell bladder cancer, potentially via tumor necrosis factor generation.
    • Systemic interferon and interleukin-2 have shown limited efficacy (approx. 20% response rate) in renal cell carcinoma, with generally short-lived responses.
    • Initial enthusiasm for interferons in renal cell carcinoma has been tempered by difficulties in reproducing results and significant side effects.

    Conclusions:

    • BRMs present intriguing therapeutic possibilities for genitourinary cancers due to their novel mechanisms and the lack of definitive treatments.
    • Understanding the complex host/tumor cell interactions is critical for optimizing the use of BRMs.
    • Further research is needed to successfully implement BRMs, alone or in combination, for genitourinary cancer treatment.

    Related Experiment Videos